Results 211 to 220 of about 143,676 (242)
Some of the next articles are maybe not open access.
Clinical Science, 1976
1. A new method of destroying thrombi in blood vessels by ultrasound and simultaneously removing them is reported. 2. Experiments were performed in twenty dogs with artificial thrombi in the iliac and femoral arteries and veins. The length of the thrombi ranged from 4 to 5 cm and the age from 12 h to 10 days. The unit used consisted of a
A. Sobbe +5 more
openaire +3 more sources
1. A new method of destroying thrombi in blood vessels by ultrasound and simultaneously removing them is reported. 2. Experiments were performed in twenty dogs with artificial thrombi in the iliac and femoral arteries and veins. The length of the thrombi ranged from 4 to 5 cm and the age from 12 h to 10 days. The unit used consisted of a
A. Sobbe +5 more
openaire +3 more sources
European Journal of Neurology, 2012
Background and purposeHemiplegia at stroke onset may be considered a contraindication for thrombolytic therapy. We describe the outcome of patients with ischaemic stroke presenting with hemiplegia and treated with intravenous alteplase (tPA).MethodsAll patients treated with tPA for acute ischaemic stroke between 1995 and 2010 were prospectively ...
Atte Meretoja +5 more
openaire +3 more sources
Background and purposeHemiplegia at stroke onset may be considered a contraindication for thrombolytic therapy. We describe the outcome of patients with ischaemic stroke presenting with hemiplegia and treated with intravenous alteplase (tPA).MethodsAll patients treated with tPA for acute ischaemic stroke between 1995 and 2010 were prospectively ...
Atte Meretoja +5 more
openaire +3 more sources
Archives of Neurology, 1996
On June6,1996, the Peripheral and Central Nervous System Drug Advisory Committee to the US Food and Drug Administration (FDA) voted 10 to 0 that tissue-type plasminogen activator (t-PA [lateplase]) is safe and effective therapy for acute ischemic stroke.
openaire +3 more sources
On June6,1996, the Peripheral and Central Nervous System Drug Advisory Committee to the US Food and Drug Administration (FDA) voted 10 to 0 that tissue-type plasminogen activator (t-PA [lateplase]) is safe and effective therapy for acute ischemic stroke.
openaire +3 more sources
Cardiologia (Rome, Italy), 1995
In this study, we assessed one particular aspect of the arrhythmogenic phenomena that occur during reperfusion secondary to thrombolysis, that is the therein involved metabolic mechanisms. The employed experimental model (isolated Langendorff-perfused rat heart) allowed us to distinguish which factor involved during ischemia, low coronary flow or low ...
B. Caro +3 more
openaire +3 more sources
In this study, we assessed one particular aspect of the arrhythmogenic phenomena that occur during reperfusion secondary to thrombolysis, that is the therein involved metabolic mechanisms. The employed experimental model (isolated Langendorff-perfused rat heart) allowed us to distinguish which factor involved during ischemia, low coronary flow or low ...
B. Caro +3 more
openaire +3 more sources
British Journal of Haematology, 2009
SummaryThrombosis in children may result in vascular occlusion and a potential loss of viability in skin, limbs or organs, or lead to the development of post thrombotic syndrome. Thrombolysis may prevent such complications, and the use of thrombolytics in children has increased in the last three decades.
openaire +3 more sources
SummaryThrombosis in children may result in vascular occlusion and a potential loss of viability in skin, limbs or organs, or lead to the development of post thrombotic syndrome. Thrombolysis may prevent such complications, and the use of thrombolytics in children has increased in the last three decades.
openaire +3 more sources
Thrombosis and Haemostasis, 2005
SummaryCardiovascular diseases are a major cause of mortality in the developed world. Efficacy of thrombolysis plays an important role in the management of acute myocardial infarction and cerebral insult both in the acute event and in the long-term outcome of these patients.
Stefan, Pfaffenberger +6 more
openaire +2 more sources
SummaryCardiovascular diseases are a major cause of mortality in the developed world. Efficacy of thrombolysis plays an important role in the management of acute myocardial infarction and cerebral insult both in the acute event and in the long-term outcome of these patients.
Stefan, Pfaffenberger +6 more
openaire +2 more sources
2001
The pharmacological use of plasminogen activators is associated with symptomatic improvement in patients with coronary artery thrombosis, peripheral arterial occlusions, and thrombosis of the venous system. Based on prospective angiographic studies and planned programs (1, 2, 3, 4, 5), thrombolysis is the only approved treatment of acute ischemic ...
Gregory J. del Zoppo, Naohisa Hosomi
openaire +2 more sources
The pharmacological use of plasminogen activators is associated with symptomatic improvement in patients with coronary artery thrombosis, peripheral arterial occlusions, and thrombosis of the venous system. Based on prospective angiographic studies and planned programs (1, 2, 3, 4, 5), thrombolysis is the only approved treatment of acute ischemic ...
Gregory J. del Zoppo, Naohisa Hosomi
openaire +2 more sources
Ultrasonics, 2008
Ultrasound energy for thrombolysis dates back to 1976. Trubestein et al. demonstrated first in vitro that a rigid wire delivery low frequency ultrasound energy could disrupt clot. These investigators also showed that this system had potential for peripheral arterial clot dissolution in vivo in animal studies [G. Trubestein, C. Engel, F. Etzel, Clinical
Robert J, Siegel, Huai, Luo
openaire +2 more sources
Ultrasound energy for thrombolysis dates back to 1976. Trubestein et al. demonstrated first in vitro that a rigid wire delivery low frequency ultrasound energy could disrupt clot. These investigators also showed that this system had potential for peripheral arterial clot dissolution in vivo in animal studies [G. Trubestein, C. Engel, F. Etzel, Clinical
Robert J, Siegel, Huai, Luo
openaire +2 more sources
Fibrinolysis, 1994
It is 47 years since the first therapeutic use of streptokinase, 35 years since the first clinical study of thrombolysis in myocardial infarction,’ 15 years since the European Cooperative study trial2 proved its efficacy, and more or less a decade since GISSI-l3 and ISIS-2.4 An update of this type traditionally has three parts: where have we been ...
openaire +2 more sources
It is 47 years since the first therapeutic use of streptokinase, 35 years since the first clinical study of thrombolysis in myocardial infarction,’ 15 years since the European Cooperative study trial2 proved its efficacy, and more or less a decade since GISSI-l3 and ISIS-2.4 An update of this type traditionally has three parts: where have we been ...
openaire +2 more sources
Neurology, 2011
To examine whether prior statin use affects outcome and intracranial hemorrhage (ICH) rates in stroke patients receiving IV thrombolysis (IVT).In a pooled observational study of 11 IVT databases, we compared outcomes between statin users and nonusers.
Engelter +23 more
openaire +3 more sources
To examine whether prior statin use affects outcome and intracranial hemorrhage (ICH) rates in stroke patients receiving IV thrombolysis (IVT).In a pooled observational study of 11 IVT databases, we compared outcomes between statin users and nonusers.
Engelter +23 more
openaire +3 more sources